Who makes Resiquimod 0.01%?

Resiquimod 0.01% is developed by Spirig Pharma Ltd..

What development phase is Resiquimod 0.01% in?

Resiquimod 0.01% is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Resiquimod 0.01%

Spirig Pharma Ltd. · Phase 2 active Small molecule

At a glance

Generic name	Resiquimod 0.01%
Sponsor	Spirig Pharma Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Resiquimod 0.01% CI brief — competitive landscape report
Resiquimod 0.01% updates RSS · CI watch RSS
Spirig Pharma Ltd. portfolio CI